Dr. Schlumbrecht on the Role of Surgical Resection in Uterine Leiomyosarcoma

Video

In Partnership With:

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the role of surgical resection in uterine leiomyosarcoma.

A prospective clinical trial comparing surgical resection with chemotherapy in uterine leiomyosarcoma would be unlikely to complete full accrual given the rarity of the disease, says Schlumbrecht.

However, retrospective data have demonstrated a potential survival advantage for patients who underwent a complete resection, particularly in those who had negative margins following surgery, says Schlumbrecht.

As such, surgical resection is advisable in eligible patients, after which chemotherapy can be considered.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology